Genelabs operates in the biotechnology and pharmacology sectors, focusing on the discovery of new candidate medications. The company employs advanced computational methods to screen and identify small molecules that bind to specific drug targets, aiming to develop effective therapeutic solutions. Genelabs serves pharmaceutical companies and research institutions, providing them with cutting-edge drug discovery services. The business model revolves around offering specialized screening assays and virtual screening services, which help clients identify potential drug compounds with desirable properties such as oral bioavailability, chemical stability, and minimal toxicity. Revenue is generated through service contracts and collaborative research agreements.

Keywords: drug discovery, biotechnology, pharmacology, computational methods, therapeutic development, screening assays, virtual screening, pharmaceutical clients, research institutions, service contracts.